Related content

Mechanisms of resistance to EGFR tyrosine kinase inhibitors: implications for patient selection and drug combination strategies

By Eyzaguirre Alexandra  

Targeted Oncology, Vol. 3, Iss. 4, 2008-10 ,pp. : 235-243

Springer Publishing Company

Access to resources Recommend Favorite

Challenges in Clinical Patient Management

By Aapro Matti S.  

Cancer Investigation, Vol. 28, Iss. 1, 2010-07 ,pp. : 14-27

Informa Healthcare

Access to resources Recommend Favorite

Targeting Vascular Endothelial Growth Factor (VEGF) for Anti-tumor Therapy, by Anti-VEGF Neutralizing Monoclonal Antibodies or by VEGF Receptor Tyrosine-kinase Inhibitors

By Schlaeppi J-M.  

Cancer and Metastasis Reviews, Vol. 18, Iss. 4, 1999-12 ,pp. : 473-481

Springer Publishing Company

Access to resources Recommend Favorite

Hypertension and targeted therapy: Part 2: Small molecule inhibitors of VEGF

By Chowdhury Simon  

Targeted Oncology, Vol. 1, Iss. 3, 2006-07 ,pp. : 172-178

Springer Publishing Company

Access to resources Recommend Favorite

Increased Hemoglobin Associated with VEGF Inhibitors in Advanced Renal Cell Carcinoma

By Harshman Lauren   Kuo Calvin   Wong Bryan   Vogelzang Nicholas   Srinivas Sandy  

Cancer Investigation, Vol. 27, Iss. 8, 2009-10 ,pp. : 851-856

Informa Healthcare

Access to resources Recommend Favorite